Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

Skip Nav Destination

Oncology (2014) 86 (2): 86–93.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases

Haoran Qi
Yichen Hou
Zhonghang Zheng
Mei Zheng
Qiang Qiao
Zihao Wang
Xiaorong Sun
Ligang Xing

BMC Cancer (2024) 24 (1)

Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors

Izzet Dogan
Nijat Khanmammadov
Anıl Yıldız
Melin Aydan Ahmed
Sezai Vatansever
Pinar Saip
Adnan Aydiner

Journal of Cancer Research and Therapeutics (2023) 19 (7): 1945.

CONCORDANCE

Kumar Prabhash
Bivas Biswas
Sachin Khurana
Ullas Batra
Ghanashyam Biswas
Suresh Hariram Advani
Prabrajya N. Mohapatra
Senthil Rajappa
Ajay Sharma
Shekhar Patil
Palanki Satya Dattatreya
Rakesh Roy
Sachin Almel
Gautam Goyal
Narayanankutty Warrier

Indian Journal of Cancer (2022) 59 (Suppl 1): S11.

Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I

Nicolas Floc'h
Sangbin Lim
Sue Bickerton
Afshan Ahmed
Jonathan Orme
Jelena Urosevic
Matthew J. Martin
Darren A.E. Cross
Byoung Chul Cho
Paul D. Smith

Molecular Cancer Therapeutics (2020) 19 (11): 2298.

Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: A real-world multicentric cohort analysis from India

Avneet Garg
Ullas Batra
Priyanshu Choudhary
Deepali Jain
Sachin Khurana
Prabhat S. Malik
Valliappan Muthu
K.T. Prasad
Navneet Singh
Tejas Suri
Anant Mohan

Current Problems in Cancer (2020) 44 (3): 100570.

Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution

Kaidi Li
Maojun Yang
Naixin Liang
Shanqing Li

Oncology Reports (2017) 37 (3): 1347.

Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis

Jingqi Zhuang
Yongfeng Yu
Ziming Li
Shun Lu

Oncotarget (2017) 8 (32): 53675.

Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

Shaohua Cui
Liyan Jiang

Tumor Biology (2017) 39 (5): 101042831770534.

Concomitance of P-gp/LRP Expression with EGFR Mutations in Exons 19 and 21 in Non-Small Cell Lung Cancers

Hong Wei
Weipeng Lu
Mei Li
Qiuping Zhang
Shen Lu

Yonsei Medical Journal (2016) 57 (1): 50.

The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors

Yu-Mu Chen
Chien-Hao Lai
Huang-Chih Chang
Tung-Ying Chao
Chia-Cheng Tseng
Wen-Feng Fang
Chin-Chou Wang
Yu-Hsiu Chung
Yi-Hsi Wang
Mao-Chang Su
Kuo-Tung Huang
Hung-cheng Chen
Meng-Chih Lin

Lung Cancer (2016) 93: 47.

Impact of Smoking Status on EGFR-TKI Efficacy for Advanced Non–Small-Cell Lung Cancer in EGFR Mutants: A Meta-analysis

Yaxiong Zhang
Shiyang Kang
Wenfeng Fang
Shaodong Hong
Wenhua Liang
Yue Yan
Tao Qin
Yanna Tang
Jin Sheng
Li Zhang

Clinical Lung Cancer (2015) 16 (2): 144.

Impact of Smoking History on the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations

Satoshi Igawa
Jiichiro Sasaki
Sakiko Otani
Mikiko Ishihara
Akira Takakura
Masato Katagiri
Noriyuki Masuda

Oncology (2015) 89 (5): 275.

Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib

Kuan-Li Wu
Ming-Ju Tsai
Chih-Jen Yang
Wei-An Chang
Jen-Yu Hung
Chun-Ju Yen
Chi-Hsiang Shen
Tzu-Yu Kuo
Jui-Ying Lee
Shah-Hwa Chou
Ta-Chih Liu
Inn-Wen Chong
Ming-Shyan Huang

Lung Cancer (2015) 88 (2): 187.

Molecular Interaction of a Kinase Inhibitor Midostaurin with Anticancer Drug Targets, S100A8 and EGFR: Transcriptional Profiling and Molecular Docking Study for Kidney Cancer Therapeutics

Zeenat Mirza
Hans-Juergen Schulten
Hasan Ma Farsi
Jaudah A. Al-Maghrabi
Mamdooh A. Gari
Adeel Ga Chaudhary
Adel M. Abuzenadah
Mohammed H. Al-Qahtani
Sajjad Karim
Jaydutt V. Vadgama

PLOS ONE (2015) 10 (3): e0119765.

Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

INFORMATION

ABOUT US

SERVICES FOR

Karger International

Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

This Feature Is Available To Subscribers Only